SNYR
SNYRHealthcareNASDAQMedical Distribution
Scan Results
Daily timeframeSNYR provides consumer health care, beauty, and lifestyle products in the United States, Canada, Mexico, and internationally. Valued at $1.2M, SNYR is a micro-cap name in its sector. It offers brain health nutritional supplements under the FOCUSfactor brand name; and lifestyle and wellness products and accessories, including tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name.
Market Cap
$1.2M
Beta
0.64
P/E (TTM)
—
P/E (Fwd)
0.55
EPS (TTM)
$-1.60
EPS (Fwd)
$0.15
ROE
—
ROA
-62.0%
Cash
$292,115
Total Debt
$27.7M
Free CF
$1.8M
52W Change
-95.3%
Annual Financials
Cash vs Debt
Where SNYR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SNYR finished 81.97% below its 150-day moving average ($0.61) and 88.17% below its 200-day moving average ($0.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNYR overbought or oversold?
At the September 3, 2026 close, SNYR's RSI(14) was 50.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SNYR carries $27.7M in total debt against $292K in cash reserves — debt is roughly 95.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $1.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has pulled back from $42.8M (2023) to $30.4M (2025), a 29% decline worth watching.
The relatively low beta of 0.64 suggests SNYR is a less volatile holding compared to the broader index. SNYR carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing SNYR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.